BMS-986301
Advanced Solid Cancers
Bristol-Myers SquibbPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Advanced Solid Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FENTANYL Gachon University Gil Medical Center | Phase 2 | B |
prl3-zumab Intra-IMMUSG Pte Ltd | Phase 2/3 | B |
Oxycodone Gachon University Gil Medical Center | Phase 2 | B |
Zalifrelimab Agenus Inc. | Phase 1/2 | CCC |
BMS-863233 Bristol-Myers Squibb | Phase 1/2 | CC |
View all 22 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →